{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T12:40:02Z","timestamp":1745757602007,"version":"3.40.4"},"reference-count":13,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,8,27]]},"abstract":"<jats:p>Recent advances in novel immunotherapeutic and targeted therapeutic agents have increased treatment options in patients with advanced metastatic melanoma. However, evidence in the literature on whether or not extracutaneous melanoma will acquire an equivalent advantage from these therapies is very scarce. In general, extracutaneous melanomas are rare and aggressive melanomas, which are clinically and biologically unique, with higher incidence of metastatic disease and poor prognosis. In this case report, we present a very rare case of a 54-year-old woman with primary pelvic retroperitoneal melanoma treated with an anti-PD-1 antibody, pembrolizumab. Furthermore, we explore the role of novel immunotherapies in the treatment of advanced melanoma.<\/jats:p>","DOI":"10.1136\/bcr-2016-216450","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T15:57:39Z","timestamp":1473782259000},"page":"bcr2016216450","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy in a rare case of primary pelvic retroperitoneal melanoma"],"prefix":"10.1136","volume":"2016","author":[{"given":"Maria Monica","family":"Talag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Alsharedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadim","family":"Bou Zgheib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda","family":"Lebowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,9,13]]},"reference":[{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6109(02)00100-7"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2890040509"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512053132327"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.5","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"issue":"(Suppl","key":"2025042705154443000_2016.sep13_4.bcr2016216450.6","first-page":"4","article-title":"Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma","volume":"16","author":"Dutcher","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.7","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-85"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.8","doi-asserted-by":"crossref","first-page":"pii: bcr2015212772","DOI":"10.1136\/bcr-2015-212772","article-title":"Perianal melanoma with a BRAF gene mutation in a young Portuguese Roma native","volume":"2016","author":"Tan","year":"2016","journal-title":"BMJ Case Rep"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605635"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.02.001"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.12","doi-asserted-by":"crossref","unstructured":"Atrash S , Makhoul I , Mizell JS , et al . Response of metastatic mucosal melanoma to immunotherapy: it can get worse before it gets better. J Oncol Pharm Pract 2016; 1\u20135 doi:10.1177\/1078155215627503. doi:10.1177\/1078155215627503","DOI":"10.1177\/1078155215627503"},{"key":"2025042705154443000_2016.sep13_4.bcr2016216450.13","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0160"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-216450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T12:15:52Z","timestamp":1745756152000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-216450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,13]]},"references-count":13,"alternative-id":["10.1136\/bcr-2016-216450"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-216450","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2016,9,13]]}}}